(HealthDay)—A class of diabetes drugs, called sodium-glucose co-transporter-2 (SGLT2) inhibitors,
Large placebo-controlled trial confirms safety of proton pump inhibitors (PPIs)
For patients taking proton pump inhibitors (PPIs) to treat gastroesophageal